Lítio e a doença de Alzheimer: novas pistas a partir de experiências celulares

Lithium para Alzheimer’s

Durante muito tempo, a conversa sobre lítio e Alzheimer’s seguiu um guião frustrante. Em laboratório e em ratinhos, o lítio consegue, de forma consistente, acalmar a proteína tau - aquela que se enrola em nós destrutivos dentro dos neurónios. Mas quando se passa para ensaios em pessoas, os ganhos tendem a desaparecer. A explicação mais comum tem sido a de sempre: o problema está na dose.

Um novo conjunto de experiências em células sugere, porém, que a história pode ser mais complexa. O lítio parece mexer em muito mais engrenagens dentro de células com características de Alzheimer’s do que se tinha mapeado - e algumas dessas engrenagens nem sequer faziam parte da lista do que os investigadores estavam à procura.

Alzheimer’s disease wrecks the brain in two well-documented ways. Twisted clumps of tau proteins build up inside neurons, and amyloid plaques – hardened protein deposits that collect in the gaps between brain cells – pile up between them. Both ruin the cell-to-cell signaling that holds memory and thinking together. 

For decades, researchers have circled lithium as a possible second front. In lab dishes and in mice, the metal reliably calmed tangled tau in Alzheimer’s.

In human clinical trials, the results turned messy – a little improvement for some, nothing for others.

The Finnish study, led by Dorit Hoffmann, a project researcher at the University of Eastern Finland (UEF), looked at what lithium is actually doing inside Alzheimer’s cells. That is a different question from what the metal was supposed to do.

Por que os ensaios anteriores falharam

A separate Harvard group offered one explanation last year. The brain naturally holds a small amount of lithium, and amyloid plaques in Alzheimer’s brains pull it out of circulation. Those plaques bind the metal so tightly that little of it reaches the surrounding cells.

That changed how people read the old trial data. If most of a patient’s lithium gets trapped in plaques, the dose reaching brain cells is far smaller than the prescription. The Harvard paper made that case from human brain tissue.

Hoffmann’s team took the next step. They wanted to know what lithium does in cells when it is not being soaked up, and whether the textbook story – that lithium just calms one overactive enzyme – told the whole story.

Testar o lítio em células

The team used two cell systems to mimic Alzheimer’s-style damage. One was a line of human cells engineered to carry a mutant tau protein that tangles easily. The other mixed mouse neurons with brain immune cells, which was closer to the real thing.

They dosed both with lithium chloride, the simple lithium salt used in psychiatric medicine, and measured the molecular changes inside the cells with sensitive, protein-tracking tools. The point was not to count tangles. The point was to map every spot that lithium touched.

What turned up was a much busier picture than the field had previously assumed. Lithium did not stop at its expected target, and the data hinted at effects on systems the team had not even been looking for.

O lítio altera as “etiquetas” da tau

Tau proteins tangle when small chemical tags – phosphate groups – get stuck onto them at the wrong spots. Researchers already knew lithium knocks off some of those tags. The Finnish results confirmed that.

The surprise sat next to it. Until this study, no one had charted how broadly lithium chloride alters tau‘s tagging in living cells. The team found several, previously unreported sites and several already flagged in Alzheimer’s tissue.

That detail moves the story. Old work cast lithium as a fix for a couple of known tagging spots. The new data show it touching a wider stretch of tau, including sites that the field has barely begun to study. This indicates a far bigger footprint.

Mais do que uma enzima

Textbook biology pins lithium’s effect on tau to one enzyme. It runs hot in Alzheimer’s brains, slapping phosphate tags onto tau in the wrong spots. Slow it down, the thinking goes, and the tags fade.

Hoffmann’s analysis suggested that this picture is too narrow. The data showed tau tagged in more places than that one enzyme alone would explain, suggesting several other tagging enzymes also respond to lithium. Not just one, but a family of enzymes.

Identifying which enzymes those are will take more work. The cell data only flag the changes; the next round of research has to pull each one apart.

O lítio altera “interruptores”

The team also turned up something further afield. Lithium chloride altered a set of cellular switches called Rho GTPases, which help cells stay structured and decide where to send signals. Several have already been tied to Alzheimer’s; others have not.

Hoffmann and Research Manager Virpi Ahola of the UEF Bioinformatics Center treat this finding as the part that opens new ground. The role of these switches in Alzheimer’s needs more work before anyone can say whether nudging them will help.

The cell models cannot answer that bigger question. They can say the switches respond, and that future drug screens have somewhere new to look.

O que vem a seguir

The Finnish work does not offer lithium chloride as a treatment. It draws a wider map of where the metal lands inside the cells of Alzheimer’s patients, and names targets that the field had not yet measured.

For the clinic, the implication is concrete. Future trials of lithium-based therapies can track a broader panel of changes, not only tau tags, so researchers can distinguish between patients who respond and those who do not based on what is happening inside their cells.

A drug in use for decades still has secrets. The Finnish team added several to the list, and named the places where the next round of research should look.